What Retatrutide Actually Is

Retatrutide is a synthetic peptide — a short chain of amino acids — designed to bind to three different receptors in the body simultaneously. Its developer, Eli Lilly, calls it a “triple-G agonist,” referring to the three pathways it activates: GLP-1, GIP, and glucagon.

If you’ve heard of Ozempic, Wegovy, Mounjaro, or Zepbound, you’ve already encountered the family retatrutide belongs to. Those drugs work by activating one or two of the same receptors. Retatrutide is the next generation — it activates all three at once.

It is currently in Phase 3 clinical trials and is not yet approved as a medicine in any major jurisdiction. The compound supplied by research peptide vendors, including Bangkok Peptides, is the same molecule being studied in those trials — provided strictly for laboratory and preclinical research use only.

How It Works — the Triple-G Pathway

The body has many receptors that influence appetite, blood sugar, and energy use. Retatrutide targets three of them. Each one does something distinct:

The key insight is the third pathway. Glucagon does something the other two don’t — it raises baseline calorie burn. Where GLP-1 and GIP work mostly on the input side (eating less, feeling full sooner, processing food differently), glucagon works on the output side (burning more energy and clearing fat from the liver).

Activating all three at once is the reason retatrutide produces results that single- and dual-agonist drugs can’t match. You’re suppressing appetite, improving how the body handles food, and increasing energy expenditure — all from one molecule.

What the Phase 2 Trial Showed

In June 2023, the New England Journal of Medicine published the results of the Phase 2 retatrutide trial conducted by Eli Lilly. The trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Participants received weekly subcutaneous injections of retatrutide at one of four doses, or placebo, for 48 weeks.

The results, by dose:

For context: in the equivalent Phase 2 trials, semaglutide produced about 14.9% weight loss at the highest dose, and tirzepatide produced about 20.9%. Retatrutide’s 24.2% is the largest figure ever recorded in a Phase 2 obesity trial.

The trial also showed that 83% of participants on the highest dose lost at least 15% of their body weight, and 26% lost at least 30%. To put 30% in perspective: that’s a 100kg person ending the trial at 70kg. From a single weekly injection. In just under a year.

The Liver-Fat Result

Beyond weight loss, retatrutide produced a result that surprised researchers: dramatic reductions in liver fat. A separate Phase 2 sub-study published in 2024 in Nature Medicine looked specifically at participants with non-alcoholic fatty liver disease (NAFLD) — a condition where fat accumulates in the liver and can progress to serious disease.

After 48 weeks, participants on retatrutide showed an 81.4% mean reduction in liver fat content at the highest dose. 86% of participants on retatrutide had complete normalisation of liver fat content (defined as ≤5%), compared with 0% in the placebo group.

This is the glucagon receptor at work. The liver is the body’s main site of glucagon activity, and engaging that receptor appears to drive fat clearance from liver tissue in a way that GLP-1-only and GLP-1+GIP drugs simply don’t replicate.

How It’s Dosed in Trials

Retatrutide is administered as a once-weekly subcutaneous injection. Like other peptides in this class, the dose is titrated upward gradually — starting low and stepping up every four weeks — to allow the body to adapt and minimise gastrointestinal side effects.

In the Phase 2 trial, the titration schedule for the 12 mg group looked roughly like this:

Weeks 1–4 at 2 mg, weeks 5–8 at 4 mg, weeks 9–12 at 6 mg, weeks 13–16 at 8 mg, then 12 mg from week 17 onward. The “start low, go slow” approach is standard across the GLP-1 drug family because rapid titration produces severe nausea.

Side effects in the trial were mostly gastrointestinal — nausea, diarrhoea, vomiting, constipation — and most were rated mild to moderate. They were also dose-dependent, which is why titration matters. Modest increases in heart rate were also observed, consistent with glucagon receptor activity.

Retatrutide vs Semaglutide vs Tirzepatide

All three compounds belong to the same broad family of incretin-mimetic peptides, but they target different combinations of receptors. The differences in trial outcomes track directly with how many pathways each one engages.

A common question: is the difference between 20.9% (tirzepatide) and 24.2% (retatrutide) really that significant? The answer is yes — but the more interesting comparison is at the higher end of the response distribution. 26% of retatrutide participants lost ≥30% of their body weight. That category essentially didn’t exist in earlier trials. We’re talking results that approach what bariatric surgery produces.

For a deeper side-by-side look, see our dedicated comparison: Retatrutide vs Tirzepatide vs Semaglutide.

Where Retatrutide Goes From Here

Eli Lilly began Phase 3 trials for retatrutide — the TRIUMPH program — in 2023, and these trials are ongoing. Phase 3 is the larger, longer-running stage that determines whether the drug gets regulatory approval for human use. Initial Phase 3 results are expected from 2026 onward, with potential FDA approval somewhere in the 2026–2027 window if the data holds.

Until then, retatrutide remains an investigational compound. It is not approved as a medicine, supplement, or therapeutic in any major jurisdiction. The version supplied by research peptide vendors is intended exclusively for laboratory and preclinical research use, not human consumption.

Sourcing Retatrutide for Research

Bangkok Peptides supplies retatrutide as a research-grade lyophilised peptide, third-party tested by Janoshik Analytical and verified to ≥99% purity by HPLC/MS. We stock 10mg, 20mg, and 30mg vials with same-day or next-day dispatch from Bangkok and tracked nationwide delivery across Thailand.

For researchers based in Thailand specifically, we maintain a dedicated Retatrutide Thailand page covering domestic supply, delivery timeframes, and Thailand-specific storage considerations. The full retatrutide product page includes current vial pricing, batch documentation, and Janoshik test reports where available.

Frequently Asked Questions